Has Saumya Das, MD received payments from drug or device companies?

Yes. Drug and device makers reported $15,760 in general payments to Saumya Das, MD across 6 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Saumya Das, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Saumya Das, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Saumya Das, MD

Clinical Cardiac Electrophysiology · Boston, MANPI 1346224508

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $15,710 of the $15,760 with a category attached, or 99.7%. 5 manufacturers reported payments, led by Boston Scientific at 57.1% of the total. Reporting peaked in 2023 at $9,000 and has fallen 74.3% since, to $2,310 in 2024.

$15,760in general payments, 2019–2025

Across 6 payments — averaging $2626.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$9K
Amgen$4K
E.r. Squibb & Sons, L.L.C.$2K
Abbott$36
AstraZeneca$14

$138,072in research payments, 2019–2025

Across 8 payments — averaging $17,259 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Abbott$138K

What the payments were for

Consulting fees$15,710100%
Food & beverage$500%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	1	$9,000
Amgen	2	$4,400
E.r. Squibb & Sons, L.L.C.	1	$2,310
Abbott	1	$36
AstraZeneca	1	$14

How this compares

$15,760 in reported general payments places this provider in the 55th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

See all clinical cardiac electrophysiology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$157,241

Medicare patients

1,462

Services billed

2,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Metoprolol Succinate	25	$190

Paid to pharmacies, not to this prescriber.

Other clinical cardiac electrophysiology in Boston

Elad AnterBoston$3.9M
Jagmeet SinghBoston$619K
Andre DavilaBoston$379K
Daniel KramerBoston$247K
Gregory MichaudBoston$244K
Laurence EpsteinBoston$172K
Leon PtaszekBoston$168K
Moussa MansourBoston$145K
Andrew LockeBoston$145K
Peter ZimetbaumBoston$144K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →